A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer

European Journal of Cancer

Volumn 42, Issue 16, 2006, Pages 2751-2756

  Canney, P A ^a   Machin, M A ^b   Curto, J ^b  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

Breast cancer; Cycooxygenase II inhibitor; Exemestane

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EXEMESTANE;

ADULT; ARTHRALGIA; ARTICLE; BLOOD CELL COUNT; BREAST CANCER; CANCER DIAGNOSIS; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; HEARTBURN; HEMATOLOGIC DISEASE; HISTOLOGY; HOT FLUSH; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; NAUSEA; NIGHT SWEAT; POSTMENOPAUSE; PRIORITY JOURNAL; STOMACH ULCER; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; AGED; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PYRAZOLES; QUALITY OF LIFE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 33750037634     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.08.014     Document Type: Article

References (20)

1. Shim J.Y., An H.J., Lee Y.H., et al. Overexpression of cyclooxygenase-2 is associated with breast carcinoma and it's poor prognostic features. Mod Pathol 16 12 (2003) 1199-1204
2. Tsujii M., and DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83 (1995) 493-501
3. Sheng H., Shao J., Kirkland S.C., et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99 9 (1997) 2254-2259
4. Oshima M., Dinchuk J.E., Kargman S.L., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 5 (1996) 803-809
5. Kawamori T., Rao C.V., Seibert K., et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58 3 (1998) 409-412
6. Masferrer J.L., Leahy K.M., Koki A.T., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60 5 (2000) 1306-1311
7. Williams C.S., Tsujii M., Reese J., et al. Host cyclooxygenase-2 modulates carcinoma growth. Clin Invest 105 (2000) 1589-1594
8. Lundholm K., Gelin J., Hyltander A., et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54 21 (1994) 5602-5606
9. Harris R.E., Robertson F.M., Abou-Issa H.M., et al. Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer. Med Hypotheses 52 (1999) 291-292
10. Zhao Y., Agarwal V.R., Mendelson C.R., et al. Estrogen biosysnthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promotor II of the CYP19 (aromatase) gene. Endocrinology 137 (1996) 5739-5742
11. Brueggemeeier R.W., Quinn A.L., Parrett M.L., et al. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140 (1999) 27-35
12. Brodie A.M., Lu Q., Long B.J., et al. Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 79 (2001) 41-47
13. Singh-Ranger G., Kirkpatrick K.L., Clark G.M., et al. Cyclooxygenase-2 (COX-2) mRNA expression correlates with progesterone receptor positivity in human breast cancer. Curr Med Res Opin 19 (2002) 1311-1341
14. Subbaramaiah K., Norton L., Gerald W., et al. Cyclooxygenase-2 is overexpressed in HER2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277 (2002) 18649-18657
15. Kaufmann M., Bajetta E., Dirix L.Y., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase iii randomized double-blind trial. J Clin Oncol 18 7 (2000) 1399-1411
16. Paridaens R., Dirix L., Lohrisch C., et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14 9 (2003) 1391-1398
17. Division of Cancer Treatment, National Cancer Institute: Guidelines for reporting of adverse drug reactions. Bethesda (MD): National Cancer Institute, 1988. Version 2.0; updated April 1999.
18. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
19. Solomayer E.-F., Diel I.J., Meyberg G.C., et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Tr 59 (2000) 271-278
20. Steinbach G., Lynch P.M., Phillips R.K.S., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New Eng J Med 342 26 (2000) 1946-1952